Article info
PDFHow to do it
‘Undiagnosing’ neurological disease: how to do it, and when not to
- Correspondence to Dr Jan Coebergh, Department of Neurology, St George's Hospitals, Blackshaw Road, Tooting SW17 0QT, UK; jan.coebergh{at}asph.nhs.uk
Citation
‘Undiagnosing’ neurological disease: how to do it, and when not to
Publication history
- Accepted March 1, 2014
- First published March 24, 2014.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies
- Neurofilament light chain as a biomarker in neurological disorders
- Presymptomatic and longitudinal neuroimaging in neurodegeneration—from snapshots to motion picture: a systematic review
- ABN joint annual meeting 2009 with the Spanish Society of Neurology
- Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration
- Parkinson's disease: chameleons and mimics
- What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies
- Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis
- Amyotrophic lateral sclerosis is not linked to multiple sclerosis in a population based study
- Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study